Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages iv86-iv95

  Pena, Michelle J ^a   De Zeeuw, Dick ^a   Mischak, Harald ^b,c   Jankowski, Joachim ^d   Oberbauer, Rainer ^e   Woloszczuk, Wolfgang ^f   Benner, Jacqueline ^f   Dallmann, Guido ^g   Mayer, Bernd ^h   Mayer, Gert ⁱ   Rossing, Peter ^j,k,l   Lambers Heerspink, Hiddo J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Biomarker Design Forschungs GmbH   (Austria)

^g BIOCRATES LIFE SCIENCES AG   (Austria)

^h Emergentec Biodevelopment GmbH   (Austria)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j STENO DIABETES CENTER   (Denmark)

^k AARHUS UNIVERSITY   (Denmark)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

biomarker panels; CKD; metabolomics; novel biomarkers; proteomics

Indexed keywords

BIOLOGICAL MARKER;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANEL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEOMICS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VALIDATION STUDY; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84939633635     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv252     Document Type: Review

References (100)

1. Gregg EW, Li Y, Wang J et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-1523
2. United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014. http://www.usrds.org/adr.aspx (16 June 2015, date last accessed)
3. Vupputuri S, Kimes TM, Calloway MO et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications 2014; 28: 10-16
4. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-830
5. Fioretto P, Stehouwer CD, Mauer M et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998; 41: 233-236
6. Moresco RN, Sangoi MB, De Carvalho JA et al. Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta 2013; 421: 17-30
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
8. ADVANCE Collaborative GroupPatel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
9. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418
10. Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920-1927
11. Anderson RJ, Bahn GD, Emanuele NV et al. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2014; 37: 2782-2788
12. Pedersen EB, Mogensen CE. Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 1976; 36: 231-237
13. Parving HH, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179
14. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
15. Haller H, Ito S, Izzo JL, Jr et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
16. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
18. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
19. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
20. Haynes R, Lewis D, Emberson J et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014; 25: 1825-1833
21. de Zeeuw D, Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3: 181-190
22. Mohanram A, Zhang Z, Shahinfar S et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-1138
23. Miao Y, Ottenbros SA, Laverman GD et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2-7
24. Zoppini G, Targher G, Chonchol M et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012; 35: 99-104
25. Magee GM, Bilous RW, Cardwell CR et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52: 691-697
26. Moriya T, Tsuchiya A, Okizaki S et al. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes. Kidney Int 2012; 81: 486-493
27. Nelson RG, Bennett PH, Beck GJ et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335: 1636-1642
28. Chaiken RL, Eckert-Norton M, Bard M et al. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 1998; 21: 2129-2134
29. Ruggenenti P, Porrini EL, Gaspari F et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35: 2061-2068
30. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486
31. Gnudi L, Viberti G, Raij L et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003; 42: 19-24
32. Premaratne E, Verma S, Ekinci EI et al. The impact of hyperfiltration on the diabetic kidney. Diabetes Metab 2015; 41: 5-17
33. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-2984
34. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673
35. Lorenzo V, Saracho R, Zamora J et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 2010; 25: 835-841
36. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 2015; 107: 1-8
37. Siwy J, Schanstra JP, Argiles A et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant 2014; 29: 1563-1570
38. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515
39. Tam FW, Riser BL, Meeran K et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009; 47: 37-42
40. Persson F, Rathcke CN, Gall MA et al. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 96: 84-89
41. Hellemons ME, Mazagova M, Gansevoort RT et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 2012; 35: 2340-2346
42. Conway BR, Manoharan D, Manoharan D et al. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int 2012; 82: 812-818
43. Fufaa GD, Weil EJ, Nelson RG et al. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015; 58: 188-198
44. Fechete R, Heinzel A, Perco P et al. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl 2011; 5: 354-366
45. Pavkov ME, Nelson RG, Knowler WC et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 2015; 87: 812-819
46. Skupien J, Warram JH, Niewczas MA et al. Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 2014; 37: 2601-2608
47. Gohda T, Niewczas MA, Ficociello LH et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524
48. Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-247
49. Morton J, Zoungas S, Li Q et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012; 35: 2201-2206
50. Agarwal R, Duffin KL, Laska DA et al. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 2014; 29: 2293-2302
51. Persson F, Rossing P, Hovind P et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-738
52. Desai AS, Toto R, Jarolim P et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011; 58: 717-728
53. Wong MG, Perkovic V, Woodward M et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2013; 83: 278-284
54. Verhave JC, Bouchard J, Goupil R et al. Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: a prospective study. Diabetes Res Clin Pract 2013; 101: 333-340
55. Pena MJ, Heinzel A, Heinze G et al. A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. PLoS One 2015; 10: e0120995
56. Schutte E, Gansevoort RT, Benner J et al. Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. Nephrol Dial Transplant 2015; 30 (Suppl 4): iv96-iv104
57. Komorowsky CV, Brosius FC, III, Pennathur S et al. Perspectives on systems biology applications in diabetic kidney disease. J Cardiovasc Transl Res 2012; 5: 491-508
58. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008; 451: 949-952
59. Merchant ML, Perkins BA, Boratyn GM et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20: 2065-2074
60. Ben Ameur R, Molina L, Bolvin C et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 2866-2875
61. Otu HH, Can H, Spentzos D et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30: 638-643
62. Bhensdadia NM, Hunt KJ, Lopes-Virella MF et al. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney Int 2013; 83: 1136-1143
63. Zurbig P, Jerums G, Hovind P et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61: 3304-3313
64. Pena M, Jankowski J, Heinze G et al. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens 2015; [Accepted]
65. Pena MJ, Lambers Heerspink HJ, Hellemons ME et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med 2014; 31: 1138-1147
66. Mischak H, Delles C, Klein J et al. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010; 17: 493-506
67. Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9: 2424-2437
68. Roscioni SS, de Zeeuw D, Hellemons ME et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013; 56: 259-267
69. Schanstra JP, Zürbig P, Alkhalaf A et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2014050423
70. Rossing K, Mischak H, Dakna M et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-1290
71. Kolch W, Neususs C, Pelzing M et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005; 24: 959-977
72. Cho EH, Kim MR, Kim HJ et al. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteomics Clin Appl 2007; 1: 352-361
73. Kim HJ, Cho EH, Yoo JH et al. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007; 6: 735-743
74. Zhang J, Yan L, Chen W et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009; 650: 16-22
75. Han LD, Xia JF, Liang QL et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta 2011; 689: 85-91
76. Hirayama A, Nakashima E, Sugimoto M et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 2012; 404: 3101-3109
77. Sharma K, Karl B, Mathew AV et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013; 24: 1901-1912
78. Niewczas MA, Sirich TL, Mathew AV et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 2014; 85: 1214-1224
79. Zhu C, Liang QL, Hu P et al. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 2011; 85: 1711-1720
80. Ng DP, Salim A, Liu Y et al. A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus. Diabetologia 2012; 55: 499-508
81. van der Kloet FM, Tempels FWA, Ismail N et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012; 8: 109-119
82. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287
83. Hellemons ME, Persson F, Bakker SJ et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2011; 34: 2078-2083
84. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953
85. Ruggenenti P, Perna A, Remuzzi G et al. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261
86. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN Trial. J Am Soc Nephrol 2015; 26: 220-229
87. DCCT/EDIC Research Groupde Boer IH, Sun W et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376
88. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
89. Mohanram A, Zhang Z, Shahinfar S et al. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008; 73: 630-636
90. Anderson S, Meyer TW, Rennke HG et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619
91. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797
92. Hansen HP, Nielsen FS, Rossing P et al. Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int Suppl 1997; 63: S49-S53
93. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282-287
94. Smink PA, Hoekman J, Grobbee DE et al. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol 2014; 21: 434-441
95. Smink PA, Miao Y, Eijkemans MJ et al. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2014; 95: 208-215
96. Heerspink HJ, Grobbee DE, de Zeeuw D. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 2014; 13: 942.
97. Nielsen SE, Schjoedt KJ, Rossing K et al. Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J Renin Angiotensin Aldosterone Syst 2013; 14: 161-166
98. Rossing K, Mischak H, Parving HH et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005; 68: 193-205
99. Andersen S, Mischak H, Zurbig P et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010; 11: 29
100. Lambers Heerspink HJ, de Zeeuw D, Sharma S et al. Urine metabolomic profile correlates with renal function and changes during atrasentan therapy in patients with diabetes and nephropathy [abstract]. J Am Soc Nephrol 2014; 25: 546A